LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a key patent covering the tumor-targeting conjugate INNO-206 linker platform technology and INNO-206 pharmaceutical compositions.
